Literature DB >> 7566971

Hematopoietic transforming potential of activated ras in chimeric mice.

R G Hawley1, A Z Fong, B Y Ngan, T S Hawley.   

Abstract

Although activating mutations in ras genes are the most common genetic abnormality in human hematologic malignancies, the role of ras mutations as an initiating event in leukemogenesis remains unclear. To assess the consequences of ectopic expression of an activated ras gene in normal hematopoietic cells in vivo, lethally irradiated mice were reconstituted with bone marrow cells infected with a mutant ras-containing retrovirus [murine stem cell virus (MSCV)-v-H-ras] based on the MSCV retroviral vector which efficiently transduces functional genes into hematopoietic stem/progenitor cells. Despite a marked myeloid leukocytosis detectable in the peripheral blood within 4 weeks of engraftment, none of 22 primary or secondary transplant recipients studied for longer periods of time presented with myeloid neoplasms. Instead, 18 of the MSCV-v-H-ras mice developed pre-T-cell thymic lymphomas and/or pre-B-cell lymphoblastic leukemia/lymphomas between 7 and 12 weeks post-transplantation. The pre-B and pre-T lymphoid tumors that arose in one animal were shown to harbor a common MSCV-v-H-ras provirus, indicating that the target cell for transformation was a bipotential lymphoid precursor. To more precisely examine the effects of activated ras expression on the behavior of hematopoietic progenitors, infected bone marrow cells were assayed in methylcellulose cultures under conditions favorable for growth of multilineage myeloid colonies or were passaged as bulk suspension cultures in the presence of various hematopoietic growth factors, including interleukin (IL)-3, IL-4, IL-6 and IL-7. MSCV-directed expression of v-H-ras selectively promoted the formation of large dense colonies comprised of monocyte-macrophages in methylcellulose cultures. When transferred to liquid cultures, the vast majority of the cells underwent terminal macrophage differentiation. By comparison, tumorigenic B-lymphoid and mixed lymphoid/myeloid cell lines were routinely established from the bulk suspension cultures, with cell lines of predominantly myeloid phenotype emerging only in IL-6-supplemented cultures. These results, considered together with previous findings, suggest that activating ras mutations could be an initiating genetic alteration in human acute lymphoblastic leukemia but are more likely to be a post-initiation change in human acute myeloid leukemia.

Entities:  

Mesh:

Year:  1995        PMID: 7566971

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL.

Authors:  C Lavau; S J Szilvassy; R Slany; M L Cleary
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

2.  Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.

Authors:  Chaitali Parikh; Ramesh Subrahmanyam; Ruibao Ren
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

3.  Cutting Edge: Codeletion of the Ras GTPase-Activating Proteins (RasGAPs) Neurofibromin 1 and p120 RasGAP in T Cells Results in the Development of T Cell Acute Lymphoblastic Leukemia.

Authors:  Beth A Lubeck; Philip E Lapinski; Jennifer A Oliver; Olga Ksionda; Luis F Parada; Yuan Zhu; Ivan Maillard; Mark Chiang; Jeroen Roose; Philip D King
Journal:  J Immunol       Date:  2015-05-22       Impact factor: 5.422

Review 4.  Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks.

Authors:  René Huber; Daniel Pietsch; Johannes Günther; Bastian Welz; Nico Vogt; Korbinian Brand
Journal:  Cell Mol Life Sci       Date:  2013-03-24       Impact factor: 9.261

5.  Bypass of senescence, immortalization, and transformation of human hematopoietic progenitor cells.

Authors:  Sergey S Akimov; Ali Ramezani; Teresa S Hawley; Robert G Hawley
Journal:  Stem Cells       Date:  2005-09-06       Impact factor: 6.277

6.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

7.  Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11.

Authors:  R G Hawley; T S Hawley; A Z Fong; C Quinto; M Collins; J P Leonard; S J Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

8.  Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia.

Authors:  Mark Y Chiang; Lanwei Xu; Olga Shestova; Gavin Histen; Sarah L'heureux; Candice Romany; M Eden Childs; Phyllis A Gimotty; Jon C Aster; Warren S Pear
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

9.  Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition.

Authors:  Craig Dorrell; Katsuto Takenaka; Mark D Minden; Robert G Hawley; John E Dick
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

10.  Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.

Authors:  Mona Meyer; Daniela Rübsamen; Robert Slany; Thomas Illmer; Kathleen Stabla; Petra Roth; Thorsten Stiewe; Martin Eilers; Andreas Neubauer
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.